We are live on ! Find out more
SLRN

ACELYRIN

Delisted

SLRN was delisted on the 21st of May, 2025.

105 hedge funds and large institutions have $183M invested in ACELYRIN in 2025 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 22 increasing their positions, 41 reducing their positions, and 42 closing their positions.

New
Increased
Maintained
Reduced
Closed

129% more call options, than puts

Call options by funds: $71K | Put options by funds: $31K

100% more funds holding in top 10

Funds holding in top 10: 24 (+2)

14.28% less ownership

Funds ownership: 87.69%73.41% (-14%)

16% less funds holding

Funds holding: 125105 (-20)

34% less capital invested

Capital invested by funds: $276M → $183M (-$93.8M)

46% less repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 41

48% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 42

Holders
105
Holders Change
-20
Holders Change %
-16%
% of All Funds
1.41%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
22
Increased
22
Reduced
41
Closed
42
Calls
$71K
Puts
$31K
Net Calls
+$40K
Net Calls Change
+$22K
Name Holding Trade Value Shares
Change
Change in
Stake
TCM
1
Tang Capital Management
California
$24.3M +$23.3M +9,818,115 New
ACMC
2
AyurMaya Capital Management Company
New Hampshire
$23.1M
BlackRock
3
BlackRock
New York
$14.3M -$513K -215,772 -4%
T. Rowe Price Investment Management
4
T. Rowe Price Investment Management
Maryland
$11.5M -$19.6M -8,222,259 -64%
MAP
5
Madison Avenue Partners
New York
$10.2M +$9.85M +4,142,640 New
Vanguard Group
6
Vanguard Group
Pennsylvania
$10.1M -$723 -304 -0%
O
7
OrbiMed
New York
$9.88M
VP
8
venBio Partners
California
$9.4M
VCIM
9
Velan Capital Investment Management
Georgia
$8.32M +$8.01M +3,366,945 New
TCM
10
Tybourne Capital Management
Hong Kong
$7.18M
GA
11
General Atlantic
New York
$6.66M
SB
12
Samsara BioCapital
California
$6.23M
PAI
13
Palo Alto Investors
California
$4.43M
Geode Capital Management
14
Geode Capital Management
Massachusetts
$4.38M +$154K +64,732 +4%
OM
15
Opaleye Management
Massachusetts
$3.99M -$1.47M -620,000 -28%
State Street
16
State Street
Massachusetts
$3.51M -$50.4K -21,205 -1%
Balyasny Asset Management
17
Balyasny Asset Management
Illinois
$3.22M +$3.1M +1,305,015 New
Alyeska Investment Group
18
Alyeska Investment Group
Illinois
$1.52M -$2.14M -900,000 -59%
Renaissance Technologies
19
Renaissance Technologies
New York
$1.48M +$316K +132,879 +28%
Northern Trust
20
Northern Trust
Illinois
$1.48M -$75.8K -31,900 -5%
JP Morgan Chase
21
JP Morgan Chase
New York
$1.46M -$64.9K -27,281 -4%
CF
22
Cantor Fitzgerald
New York
$1.45M +$1.4M +588,664 New
Charles Schwab
23
Charles Schwab
California
$1.35M -$166K -69,899 -11%
TL
24
TowerView LLC
New York
$1.33M +$1.28M +540,000 New
Goldman Sachs
25
Goldman Sachs
New York
$868K -$520K -218,503 -38%

SLRN Hedge Fund Activity: Q1 2025 in Review

105 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in ACELYRIN (SLRN) for Q1 2025, worth a combined $183M — down 34% from $276M a quarter earlier.

Sellers outnumbered buyers: 42 funds closed out of SLRN and 22 opened new positions — a net loss of 20 holders — while 41 trimmed existing stakes and 22 added.

The largest buyer was Tang Capital Management, opening a new position worth an estimated $23.3M. The largest seller was T. Rowe Price Investment Management, cutting an estimated $19.6M.

  • 105 institutional investors held ACELYRIN (SLRN) as of Q1 2025, down from 125 in Q4 2024.
  • Funds reported $183M of ACELYRIN stock for Q1 2025, down 34% quarter-over-quarter.
  • 22 funds opened new ACELYRIN positions in Q1 2025 and 42 closed out, a net change of -20 holders.
  • The largest ACELYRIN buyer in Q1 2025 was Tang Capital Management, an estimated $23.3M added.
  • The largest ACELYRIN seller in Q1 2025 was T. Rowe Price Investment Management, an estimated $19.6M sold.

Based on aggregated 13F filings for Q1 2025.